Among patients with acute coronary syndromes undergoing a procedure such as angioplasty, those who received platelet function tests before receiving antithrombotic therapy to determine appropriate ...
LOS ANGELES — Patients with intracranial aneurysm who respond poorly to the antiplatelet drug clopidogrel when treated with flow diversion using the Pipeline embolization device (Medtronic) have ...
The RECLOSE 2–ACS (Responsiveness to Clopidogrel and Stent Thrombosis 2–ACS) trial from Italy provides new information about platelet reactivity but doesn't answer any of the key questions about the ...
When skin is cut or damaged, tiny cell fragments circulating in the blood, called platelets, arrive at the injury and spread out to stop the blood from leaking out. Once enough layers of platelets ...
The document follows two earlier consensus documents, released in 2013 and 2016. Dominick Angiolillo, MD, PhD (University of Florida College of Medicine – Jacksonville), senior author of the paper, ...
June 6, 2012 (Munich, Germany) — A new substudy of the ISAR-REACT-4 trial has found that those patients with high on-clopidogrel-treatment platelet reactivity (HPR) randomized to bivalirudin (Angiomax ...
Although switching from clopidogrel to the more potent antiplatelet agent prasugrel generally eliminates high on-treatment platelet reactivity in stable patients following percutaneous coronary ...
Platelets are a type of blood cell. They play an important role in healing injuries that result in bleeding. Platelets help your body to form blood clots and stop bleeding. Some people’s platelets don ...
Ado-trastuzumab emtansine (T-DM1) treatment results in grade 3-4 thrombocytopenia in 8%-13% of patients. Prior in vitro studies reported T-DM1 inhibition of megakaryocyte maturation as the cause of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results